John Schembri files SEC Form 4 disclosures for Global Blood Therapeutics, Inc.. They have made 1 open-market trade across 1 company since 2015, most recently 2016-02-01.
CIK 0001629137
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $32K since 2015, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GBT | 2,594 | $178K |
Shares reported on the most recent Form 4, priced at the 2016-02-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GBT | BUY | 2015-08-17 | 2016-01-07 | $21.57 | $32K | -11.6% | -34.3% | -9.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.